Results 151 to 160 of about 71,888 (256)

Exploring individualized crovalimab dosing in PNH through in silico modelling: Potential for improved convenience and cost efficiency

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, acquired haematopoietic stem cell disorder. Crovalimab, a complement C5‐inhibitor, is approved for PNH and can be self‐administered subcutaneously every 4 weeks, offering a more convenient route than intravenous C5‐inhibitors.
Mendy ter Avest   +4 more
wiley   +1 more source

Intervention delivery for embedded pragmatic clinical trials: Development of a tool to measure complexity. [PDF]

open access: yesContemp Clin Trials, 2023
Staman KL   +12 more
europepmc   +1 more source

Ceftriaxone‐induced liver injury: Incidence, phenotypic characterization and predictive factors

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Introduction Ceftriaxone is a widely used third‐generation cephalosporin in hospitalized patients. Although generally considered safe, it has been associated with hepatobiliary complications and emerging reports of drug‐induced liver injury (DILI). However, data on its true incidence, phenotypic patterns, and predictors remain limited. This study aimed
Mohamed Hatem   +5 more
wiley   +1 more source

Ethics challenges in sharing data from pragmatic clinical trials. [PDF]

open access: yesClin Trials, 2022
Morain SR   +3 more
europepmc   +1 more source

Impact of cumulative glucocorticoid exposure on vancomycin clearance in hospitalized children: A retrospective cohort study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Prior glucocorticoid exposure is associated with modestly increased vancomycin clearance in hospitalized children, partly mediated by renal function and inflammation and may contribute to subtherapeutic early drug exposure. Abstract Introduction Augmented renal clearance (ARC) can lead to subtherapeutic vancomycin exposure in children.
Kouki Tomari   +6 more
wiley   +1 more source

Exposure to CYP2C19‐metabolized drugs following acute stroke: A longitudinal cohort study to inform implementation of CYP2C19 genotype testing

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Cytochrome P450 2C19 (CYP2C19) genotype testing is recommended to guide antiplatelet selection after ischaemic stroke and transient ischaemic attack. CYP2C19 also metabolizes several commonly prescribed non‐antiplatelet drugs. We aimed to quantify exposure to CYP2C19‐metabolized drugs in stroke patients at hospital discharge and during ...
Cleodie C. Swire   +3 more
wiley   +1 more source

Recurring and Emerging Ethical Issues in Pragmatic Clinical Trials. [PDF]

open access: yesCirc Cardiovasc Qual Outcomes
Propes C, O'Rourke PP, Morain SR.
europepmc   +1 more source

Glucocorticoid exposure and initiation of SSRIs among patients with rheumatoid arthritis: A nested case–control study in UK primary care

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim The immune system might affect the development of anxiety disorders, though mechanisms remain unclear. This nested case–control study investigates whether use of glucocorticoids, potent immunosuppressants, is associated with SSRI initiation (a proxy for pharmacologically treated mental disorders, predominantly depression and/or anxiety).
Elise J. Heesbeen   +4 more
wiley   +1 more source

Correction: Miglustat as a Treatment for Adults with Tangier Disease Neuropathy: The MUSTANG N‑of‑1 Trial with 21 months Clinical Observation

open access: yesNeurology and Therapy
Andrew Cook   +14 more
doaj   +1 more source

Home - About - Disclaimer - Privacy